B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

TOP2B

MOLECULAR TARGET

DNA topoisomerase II beta

UniProt: Q02880NCBI Gene: 71558 compounds

TOP2B (DNA topoisomerase II beta) is targeted by 8 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting TOP2B

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1amsacrine4.82123
2decernotinib2.208
3amg 9002.087
4azd 81861.795
5Digitoxin1.102
6Topotecan1.102
7Ciprofloxacin0.691
8Ethidium0.691

About TOP2B as a Drug Target

TOP2B (DNA topoisomerase II beta) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 8 compounds with documented TOP2B interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

TOP2B inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.